We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$115M
Cap. Flow %
6.95%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Consumer Staples 0.52%
3 Financials 0.09%
4 Technology 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
176
DELISTED
Esperion Therapeutics
ESPR
– –
-102
Closed -$9.98K
LH icon
177
Labcorp
LH
$27.4B
– –
-2,277
Closed -$247K
MDT icon
178
Medtronic
MDT
$117B
– –
-5,000
Closed -$390K
MNKD icon
179
CALL
MannKind Corp
MNKD
$1.34B
– –
-20
Closed -$1K
PRPO icon
180
Precipio
PRPO
$55.2M
– –
0
– -$1K
RDNT icon
181
RadNet
RDNT
$6.05B
– –
-26,525
Closed -$223K
RGEN icon
182
PUT
Repligen
RGEN
$10.3B
– –
-100,000
Closed -$3.04M
UTHR icon
183
United Therapeutics
UTHR
$22.2B
– –
-1,481
Closed -$255K
VNDA icon
184
CALL
Vanda Pharmaceuticals
VNDA
$329M
– –
-100,000
Closed -$930K
VNDA icon
185
PUT
Vanda Pharmaceuticals
VNDA
$329M
– –
-100,000
Closed -$930K
CTLT
186
DELISTED
CATALENT, INC.
CTLT
– –
-6,429
Closed -$200K
ALIM
187
DELISTED
Alimera Sciences
ALIM
– –
-15,460
Closed -$1.16M
EIGR
188
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,054
Closed -$8.99M
EIGR
189
PUT
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-222
Closed -$1.89M
RAD
190
DELISTED
Rite Aid Corporation
RAD
– –
-1,253
Closed -$218K
LCI
191
DELISTED
Lannett Company, Inc.
LCI
– –
-1,098
Closed -$297K
WCG
192
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-2,690
Closed -$246K
ONCE
193
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-15,000
Closed -$1.16M
ALDR
194
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-150,000
Closed -$4.33M
EXAC
195
DELISTED
Exactech Inc
EXAC
– –
-7,905
Closed -$203K
SCAI
196
DELISTED
Surgical Care Affiliates, Inc.
SCAI
– –
-7,020
Closed -$241K
AMSG
197
DELISTED
Amsurg Corp
AMSG
– –
-3,328
Closed -$205K
AEGR
198
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-381,100
Closed -$9.97M
DYAX
199
PUT
DELISTED
DYAX CORPORATION
DYAX
– –
-400,000
Closed -$6.7M
PCYC
200
DELISTED
PHARMACYCLICS INC
PCYC
– –
-12,000
Closed -$3.07M
5 6 7
8
9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $115M of net new capital in Q2 2015, opening 55 new positions and adding to 41 existing holdings. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.4M trimmed.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.